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Intradermal (ID) BCG injection provides incomplete protection against TB in humans and experimental
models. Alternative BCG vaccination strategies may improve protection in model species, including
rhesus macaques. This study compares the immunogenicity and efﬁcacy of BCG administered by ID and
intravenous (IV) injection, or as an intratracheal mucosal boost (ID þ IT), against aerosol challenge with
Mycobacterium tuberculosis Erdman strain. Disease pathology was signiﬁcantly reduced, and survival
improved, by each BCG vaccination strategy, relative to unvaccinated animals. However, IV induced
protection surpassed that achieved by all other routes, providing an opportunity to explore protective
immunological mechanisms using antigen-speciﬁc IFN-g ELISpot and polychromatic ﬂow cytometry
assays. IFN-g spot forming units and multifunctional CD4 T-cell frequencies increased signiﬁcantly
following each vaccination regimen and were greatest following IV immunisation. Vaccine-induced
multifunctional CD4 T-cells producing IFN-g and TNF-a were associated with reduced disease pathol-
ogy following subsequent M.tb challenge; however, high frequencies of this population following M.tb
infection correlated with increased pathology. Cytokine producing T-cells primarily occupied the CD4
transitional effector memory phenotype, implicating this population as central to the mycobacterial
response, potentially contributing to the stringent control observed in IV vaccinated animals. This study
demonstrates the protective efﬁcacy of IV BCG vaccination in rhesus macaques, offering a valuable tool
for the interrogation of immunological mechanisms and potential correlates of protection.
Crown Copyright © 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tuberculosis (TB) is a global health problem, with a third of the
world's population estimated to be infected by Mycobacterium
tuberculosis (M.tb); currently, there are 9 million new infections
and 1.5 million deaths annually [1,2]. Bacille Calmette-Gurein
(BCG), the only licenced TB vaccine protects children from devel-
oping severe TB [3]. However, the levels of protection conferred
against pulmonary TB in adults are variable ranging from 0 to 80%
depending on geographical location [4], and it is unsuitable for usee).
vier Ltd. This is an open access artiin people whose immune system is compromised. Vaccination is
widely accepted to be the most effective method for control of in-
fectious disease, and improved vaccines against TB are desperately
needed. A surrogatemarker that could predict the potential efﬁcacy
of new vaccine candidates would accelerate the development
process, but correlates of protection have yet to be identiﬁed.
Without validated correlates, vaccine efﬁcacy can only be deter-
mined though large scale clinical trials involving thousands of at-
risk individuals in endemic countries [5]; such studies take a long
time, are logistically complex and expensive. Preclinical animal
models provide a critical component in the development process
for new vaccines, as challenge studies can not only predict the
effectiveness of vaccines in humans but they also provide the op-
portunity to identify and validate correlates of protection. Non-cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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tuberculosis because of their close similarity to humans [6e8], and,
as in humans, intradermally (ID) delivered BCG affords macaques
variable levels of protection against experimental challenge with
M. tb (Langermans 2002, Verreck 2009, Sharpe 2010).
In the search to identify immune and or clinical biomarkers of
disease and immune correlates of protection, a vaccine regimen
inducing 100% protectionwould provide an invaluable tool. Studies
published in the early 1970's revealed that BCG delivered intrave-
nously (IV) gave superior protection to that afforded when it was
delivered by other routes (intradermal (ID) subcutaneous (SC) or
intramuscular (IM)) in rhesus macaques [9e12]. IV BCG therefore
has the potential to improve upon the efﬁcacy afforded by the
conventionally used BCG vaccination and increase the opportunity
to identify correlates of protection. BCG revaccination regimens
using a primary and secondary ID vaccination have been shown to
enhance protection against pulmonary M. bovis infection in cattle
[13], provide improved early protection against M.tb in mice [14]
and moderate improvements in protection against M.tb infection
in people [15,16]; these improvements were dependant on
geographical location of the study cohort. Murine studies suggest
immunisation delivered directly to the respiratory mucosa may
provide a more effective route of vaccination [17,18] and have
indicated that intranasal delivery of a second BCG vaccination
improved the outcome of M. tb challenge compared to a single ID
BCG vaccination [19]. These studies taken together suggest that the
efﬁcacy afforded by multiple applications of BCG are improved by
delivery of the second BCG vaccination to the lung.
There is no validated correlate of protection against M.tb infec-
tion but both a cell mediated T-helper 1 (Th1) response from CD4 T-
cells [20] and an MHC-I restricted CD8 response [21] are known to
be important for successful control of disease. In the absence of a
true correlate, functional markers such as IFN-g expression are
measured to assess vaccine immunogenicity. There is evidence that
the quality of the T-cell response is important to the induction of T-
cell memory [22], and multifunctional CD4 cells expressing com-
binations of the cytokines IFN-g, TNF-a and IL-2 are involved in the
active phase of disease [23] and provide correlates of vaccine-
induced protection [24e26], although not all reports support this
latter role [27]. In addition to the induction of the speciﬁc effector
T-cells (TEM) needed to execute inﬂammatory functions in the
defence against M. tb, a successful TB vaccine will also need to
induce persistent T-cell memory populations. Whilst TEM pop-
ulations have been detected following systemic BCG vaccination
[28], it has been hypothesised that the current BCG vaccination
induces TEM populations capable of short term control of M.tb
infection, but induces weakly the central memory T cell (TCM)
populations required for long-term protection [29].
Previous macaque studies that have revealed the potential for
route of delivery to enhance the efﬁcacy afforded by BCG [9e12]
were conducted at a time before the advent of modern immuno-
logical tools, which restricted the ability to interrogate the immune
response and identify correlates of protection. This study sought to
characterise the immunological proﬁles induced by BCG when
delivered either intravenously or in an intradermal prime/mucosal
boost regimen with the immunogenicity of ID-delivered vaccina-
tion, and by comparing the efﬁcacy afforded by each vaccination
delivery route against high dose M.tb aerosol challenge, elucidate
potential correlates of protective immunity.
2. Materials and methods
2.1. Experimental animals
Twenty-four, three-year-old, male rhesus macaques of Indiangenotype were obtained from an established UK breeding colony.
Absence of previous exposure to mycobacterial antigens was
conﬁrmed by a tuberculin skin test and screening using an ex-vivo
IFN-g ELISPOT (MabTech, Nacka. Sweden) to measure responses to
mycobacterial antigens: PPD (SSI, Copenhagen, Denmark), and
pooled 15-mer peptides of ESAT6 and CFP10 (Peptide Protein
Research LTD, Fareham, U.K.).
Animals were housed in compatible social groups, in accordance
with the Home Ofﬁce (UK) Code of Practice for the Housing and
Care of Animals Used in Scientiﬁc Procedures (1989), and the Na-
tional Committee for Reﬁnement, Reduction and Replacement
(NC3Rs), Guidelines on Primate Accommodation, Care and Use,
August 2006 (NC3Rs, 2006). Animals were sedated by intramus-
cular (IM) injection of ketamine hydrochloride (Ketaset, 100mg/ml,
Fort Dodge Animal Health Ltd, Southampton, UK; 10 mg/kg) for
procedures requiring removal from their housing. None of the an-
imals had been used previously for experimental procedures and
each socially compatible group was randomly assigned to a
particular study treatment. All animal procedures and study design
were approved by the Public Health England, Porton Down Ethical
Review Committee, and authorized under an appropriate UK Home
Ofﬁce project license.
2.2. Vaccination
A plan of the vaccination strategy and timing of the aerosol
challenge is shown in Fig. 1. Twelve animals (groups A and B) were
immunised ID in the upper left arm with 100 ml BCG vaccine,
Danish strain 1331 (SSI, Copenhagen, Denmark). Six animals
(group C) were immunised IV with 1000 ml BCG vaccine into the
femoral vein of the left leg. Twelve weeks after primary ID
vaccination, 6 animals (group B) received a second vaccination
with 1000 ml BCG vaccine delivered using an endotracheal catheter
gauge 8 FG inserted into the lung to a depth of 15 cm, with the
catheter ﬂushed through using 0.5 ml sterile PBS. BCG vaccine was
prepared for intradermal or intravenous administration according
to manufacturer's instructions for preparation of vaccine for
administration to human adults. This involved by addition of 1 ml
Sautons diluent to a vial of vaccine, to give a suspension of BCG at
an estimated concentration of 2  106 to 8  106 CFU/ml. Seven
vials of reconstituted vaccine were combined to provide the
preparation for IV inoculation. For delivery to the lung, four vac-
cine vials were each reconstituted with 1 ml of sterile PBS and
combined together immediately prior to administration to give an
estimated concentration of 2  107 to 8  107 CFU/ml. Vaccina-
tions were administered within 1 h of vaccine reconstitution. The
viability of the BCG vaccine was conﬁrmed to be within the ex-
pected range for the batch on each occasion. The intradermal
vaccination sites were monitored and assessed for local reactions
after vaccination with BCG.
2.3. M. tuberculosis challenge strain
The Erdman K01 stock (HPA-Sept 2011) used for challenge was
prepared from stocks of theM. tuberculosis Erdman strain K 01 (BEI
Resources). A stock suspension was initially prepared from a 5 ml
bacterial starter culture originally generated from colonies grown
on Middlebrook 7H11 supplemented with oleic acid, albumin,
dextrose and catalase (OADC) selective agar (BioMerieux, UK). A
liquid batch culturewas then grown to logarithmic growth phase in
7H9 medium (Sigma-Aldrich, UK) supplemented with 0.05% (v/v)
Tween 80 (Sigma-Aldrich, UK). Aliquots were stored at 80 C. The
titre of the stock suspension was determined from thawed aliquots
by enumeration of colony forming units cultured ontoMiddlebrook
7H11 OADC selective agar.
Fig. 1. Experimental study design.
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Twenty one weeks after primary vaccination of animals in
groups A, B and C with BCG, the immunised animals, together with
six unvaccinated animals (Group D), were challenged by exposure
to aerosols ofM. tb (Fig. 1). as previously described [30e32]. Mono-
dispersed bacteria in particles were generated using a 3-jet Collison
nebuliser (BGI) and, in conjunction with a modiﬁed Henderson
apparatus [33], delivered to the nares of each sedated primate via a
modiﬁed veterinary anaesthesia mask. Challenge was performed
on sedated animals placed within a ‘head-out’, plethysmography
chamber (Buxco, Wilmington, North Carolina, USA) to enable the
aerosol to be delivered simultaneously with the measurement of
respired volume. The aerosol delivery process was designed to
result in the deposition of a target dose of 100 CFU in the lungs. The
number of bacilli deposited and retained in the lungs of macaques
cannot be measured directly and quantiﬁcation of the dose must be
calculated from the concentration of viable organisms in the
aerosol (Caero) and the volume of aerosol inhaled by the animal.
This ‘presented dose’ (PD) is the number of organisms that the
animals inhale. Caero is either measured directly using air sampling
within the system or may be calculated using the concentration of
organisms in the nebulizer (Cneb) and a ‘spray factor’ that is a
constant derived from data generated for the speciﬁc organism
with identical aerosol exposure parameters. The calculations to
derive the PD and the retained dose (the number of organisms
assumed to be retained in the lung) have been described previously
for high/medium aerosol doses [30,31]. The assumed retained dose
was calculated from the PD by applying a retention factor. Reten-
tion factors for rhesus macaques are described by Harper and
Moreton [34]. Challenge was conducted such that one animal from
each group was exposed in sequence (in the group order D, A, B, C)
with the cycle repeated until all animals were exposed.2.5. Clinical procedures
Animals were monitored daily for behavioural abnormalities
including depression, withdrawal from the group, aggression, and
clinical changes in feeding patterns, respiration rate and coughing.
On each occasion that required blood sample collection, aerosolchallenge or euthanasia, animals were weighed, rectal temperature
measured and examined for gross abnormalities. Red blood cell
(RBC) haemoglobin levels were measured using a HaemaCue hae-
moglobinometer (Haemacue Ltd, Dronﬁeld, UK) to identify the
presence of anaemia, and erythrocyte sedimentation rates (ESR)
were measured using the Sediplast system (Guest Medical, Eden-
bridge, UK) to detect and monitor inﬂammation induced by infec-
tion with M. tb.
The time of necropsy, if prior to the end of the planned study
period, was determined by experienced primatology staff and
based on a combination of the following adverse indicators:
depression or withdrawn behaviour, abnormal respiration (dysp-
noea), loss of 20% of peak post-challenge weight, ESR levels
elevated above normal (>20mm), haemoglobin level below normal
limits (<100 g/dL), increased temperature (>41 C) and severely
abnormal thoracic radiograph.
2.6. Immune response analysis: Interferon-gamma (IFN-g) ELISpot
Peripheral blood mononuclear cells were isolated from heparin
anti-coagulated blood using standard methods. An IFN-g ELISpot
assay was used to estimate the number of, and IFN-g production
capacity of, mycobacteria-speciﬁc T cells in PBMCs using a human/
simian IFN-g kit (MabTech, Nacka. Sweden), as described previ-
ously [31]. In brief, PBMCs were cultured with 10 mg/ml PPD (SSI,
Copenhagen, Denmark), or without antigen, in triplicate, and
incubated for 18 h. Phorbol 12-myristate (Sigma-Aldrich Dorset,
UK) (100 ng/ml) and ionomycin (CN Biosciences, Nottingham, UK)
(1 mg/ml) were used as a positive control. After culture, spots were
developed according to the manufacturer's instructions. De-
terminations from triplicate tests were averaged. Data were ana-
lysed by subtracting the mean number of spots in the cells for
medium-only control wells from the mean counts of spots in
wells with cells and antigen or peptide pools.
2.7. Intracellular cytokine staining and memory T-cell analysis
2.7.1. Polyfunctional intracellular cytokine staining and antigen-
speciﬁc memory T-cell assay
Intracellular cytokine staining (ICS) was performed using
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mented with L-glutamine (2 mM), penicillin (50 U/ml) strepto-
mycin (50 mg/ml) (all from Sigma Aldrich, Gillingham, UK) and 10%
heat-inactivated foetal bovine serum (Labtech Ltd, Uckﬁeld, UK).
These cells were stimulated with a 10 mg/ml solution of CD28 and
CD49d co-stimulatory antibodies (both from BD Biosciences, Ox-
ford, UK) and either 10 mg/ml PPD (SSI, Copenhagen, Denmark),
5 mg/ml SEB (Sigma Aldrich, Gillingham, UK), or R10 medium alone
as negative control, for a total of 6 h at 37 C, in a 5% CO2 supple-
mented incubator. Following the initial 2 h of incubation, the pro-
tein transport inhibitor Brefeldin-A (Sigma Aldrich, Gillingham, UK)
was added to the incubation mixture at a ﬁnal concentration of
10 mg/ml. Following incubation, cells were washed with FACS buffer
consisting of PBS þ1% FCS and incubated for 30 min at room tem-
perature with optimal dilutions of the amine-reactive Live/Dead
Fixable Red viability cell stain (Life Technologies, Renfrew, UK) and
the antibodies CD4 APC-H7, CD8 PerCP-Cy5.5, CD95 Pe-Cy7 (all
from BD Biosciences, Oxford, UK), CD28 BV-421 (Biolegend, Lon-
don, UK), CCR7-PE (eBioscience, Hatﬁeld, UK), CD14-ECD and
CD20-ECD (both from Beckman Coutler, High Wycombe, UK).
Following surface marker staining, the cells were washed and then
permeabilised by incubation at room temperature for 15 min with
Fix/Perm reagent (BD Biosciences, Oxford, United Kingdom).
Further cell washes were applied using Permwash buffer (BD Bio-
sciences, Oxford, United Kingdom), before staining for intracellular
antigens by incubation at room temperature for 30 min with the
antibodies CD3-AF700, IFN-g-FITC, TNF-a-BUV395 (all from BD
Biosciences, Oxford, United Kingdom), and IL-2-APC (Miltenyi
Biotech Ltd, Bisley, UK). BD Compbeads (BD Biosciences, Oxford,
UK) were labelled with the above ﬂuorochromes for use as
compensation controls. Following antibody labelling, cells and
beads were washed by centrifugation and ﬁxed in 4% para-
formaldehyde solution (Sigma Aldrich, Gillingham, UK) prior to
ﬂow cytometric acquisition.
2.7.2. Flow cytometric acquisition and analysis
Cells were analysed using a ﬁve laser LSRII Fortessa instrument
(BD Biosciences, Oxford, UK) and data were analysed using FlowJo
(version 9.7.6, Treestar, Ashland, US). Cytokine-producing T-cells
were identiﬁed using a forward scatter-height (FSC-H) versus side
scatter-area (SSC-A) dot plot to identify the lymphocyte population,
to which appropriate gating strategies were applied to exclude
doublet events, non-viable cells, monocytes (CD14þ) and B cells
(CD20þ). For ICS analysis, sequential gating through CD3þ, followed
by CD4þ or CD8þ gates were used before individual cytokine gates
to identify IFN-g, IL-2 and TNF-a producing populations. Poly-
functional cells were identiﬁed using Boolean gating combinations
of individual cytokine-producing CD4 or CD8 T-cells. Antigen-
speciﬁc T-cell memory proﬁles were identiﬁed by applying a
summed CD4 or CD8 cytokine Boolean combination, followed by
gating for CD95 surface staining. Differentiation of effector to
central memory T-cell populations was established by CD28 and
CCR7 expression (Figs. 5 and 6). The software package PESTLE
(version 1.7) was used for background subtraction to obtain
antigen-speciﬁc polyfunctional ICS and memory T-cell cytokine
responses, and SPICE (version 5.35) was used to generate graphical
representations of ﬂow cytometry data (Mario Roederer, Vaccine
Research Centre, NIAID, NIH).
2.8. Necropsy
Animals were anaesthetised and clinical data collected. Blood
samples were taken prior to euthanasia by intra-cardiac injection of
a lethal dose of anaesthetic (Dolelethal, Vetoquinol UK Ltd, 140 mg/
kg). A post-mortem examination was performed immediately andgross pathological changes were scored using an established sys-
tem based on the number and extent of lesions present in the lungs,
spleen, liver, kidney and lymph nodes, as described previously
[Sharpe 2010]. Samples of spleen, liver, kidneys and tracheobron-
chial, inguinal and axillary lymph nodes were removed and
sampled for quantitative bacteriology. The lungs, including the
heart and lung-associated lymph nodes, were removed intact. The
lymph nodes were measured and examined for lesions. The com-
plete lung set was ﬁxed by intra-tracheal infusion with 10% neutral
buffered formalin (NBF) using a syringe and 13CH Nelaton catheter
(J.A.K. Marketing, York, UK). The catheter tip was inserted into each
bronchus in turn via the trachea; the lungs were infused until they
were expanded to a size considered to be normal inspiratory di-
mensions, and the trachea ligated to retain the ﬂuid. The infused
lung was immersed in 10% NBF. In addition, samples of kidneys,
liver, spleen, and sub-clavicular, hepatic inguinal and axillary
lymph nodes were ﬁxed in 10% NBF.
2.9. Lung imaging
Thoracic radiographs (SP VET 3.2, Xograph Ltd) were acquired
using mammography ﬁlm (Xograph Imaging Systems Ltd, Tetbury,
UK) before and every 2 weeks after exposure toM. tb. Evaluation of
disease was performed by an experienced consultant thoracic
radiologist blinded to the animal group and clinical status using a
pre-determined scoring system based on the amount and distri-
bution of inﬁltrate. The lung was divided into four zones (left and
right sides divided at the anterior aspect of the ﬁfth rib) and the
disease burden scored in each area according to the system
0 ¼ normal; 1 ¼<10% abnormal; 2 ¼> 10% < 50% abnormal;
3 ¼> 50% < 75% abnormal; 4 ¼> 75% abnormal. The scores for each
zone were summed to provide the total radiographic score where
the maximum score was 16.
2.10. Magnetic resonance imaging
The ex-vivo expanded, ﬁxed lungs were set in 2% agarose
(Sigma-Aldrich, UK) and images were taken using a 3.0 T 750 MRI
Scanner (General Electric Healthcare, Milwaukee, WI, USA) as
described previously [31]. This enabled evaluation of the pulmo-
nary disease burden at the end of the study period. Lung lesions
were identiﬁed in MR images from their signal intensity and
nodular morphology relative to normal lung parenchyma.
2.11. Lesion analysis/quantiﬁcation (Stereology)
Lung lesions were identiﬁed onMR images based on their signal
intensity and nodular morphology relative to more normal lung
parenchyma. The total lung and lesion volume relative to the ﬁxed
tissue was determined using the Cavalieri method applied to MRI
image stacks, and then expressed as a ratio to provide a measure of
disease burden in each animal, as previously described [31,32].
Analyses of lesion volume on magnetic resonance (MR) images
were performed with the investigators reading the images blind to
treatment groups.
2.12. Pathology studies
The ﬁxed lungs were removed from the agar, sliced serially and
lesions counted as described previously [35]. Each lung lobe was
evaluated separately and discrete lesions were counted in the pa-
renchyma. Where lesions had coalesced, these were measured and
recorded. Lung-associated lymph nodes, particularly around the
tracheal bifurcation, were dissected and weighed. The remaining
tissues were examined during trimming.
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Representative samples from each lung lobe and other organs,
were processed to parafﬁn wax, sectioned at 3e5 mm and stained
with haematoxylin and eosin (HE). For each lung lobe, tissue slices
containing obvious lesionswere chosen for histological examination.
Where gross lesionswere not visible, a samplewas taken from a pre-
deﬁned anatomical location from each lobe to establish consistency
between animals. Sections of lung associated lymph nodes. The
nature and severity of the microscopic lesions was evaluated sub-
jectively by a pathologist who was blinded to prevent bias. In the
lung, each lobe section was assigned a consolidation score as fol-
lows: no abnormality ¼ 0; very small, very few lesions, <10%
consolidation ¼ 1; few or small lesions, 10e20% consolidation ¼ 2;
medium sized lesions, 20e33% consolidation ¼ 3; moderately sized
lesions, 33e50% consolidation ¼ 4; large lesions, moderately
extensive pneumonia, 50e80% consolidation ¼ 5; extensive pneu-
monia >80% consolidation¼ 6. A total score for each lung, andmean
consolidation score per lobe, was calculated for each group. In non-
pulmonary tissue, the occurrence of tuberculosis was scored as
present or absent.
2.14. Bacteriology
The spleen, kidneys, liver and tracheobronchial lymph nodes
were sampled for the presence of viable M.tb post-mortem [32].
Weighed tissue samples were homogenized in 2 ml of sterile water,
and either serially diluted in sterile water prior to being plated or
plated directly onto Middlebrook 7H11 OADC selective agar. Plates
were incubated for 3 weeks at 37 C and resultant colonies were
conﬁrmed as M.tb and counted.
2.15. Statistical analyses
Comparison of ex-vivo ELISpot assay responses was completed
using the area under the curve (AUC) of each animal's response
calculated using Sigmaplot version 10 (Systat Software Inc, Houn-
slow, UK). AUC values were compared between test groups using the
non-parametric Mann-Whitney U test, Minitab version 15 (Minitab
Ltd, Coventry, UK). To compare T-cell functional andmemory proﬁles
measured by polyfunctional ﬂow cytometry, T-cell subset fre-
quenciesmeasured in eachvaccinationgroupwere comparedusing a
Wilcoxon-rank test at each analysis time-point (SPICE v 5.35). Simi-
larly, vaccine-induced changes in T-cell functional proﬁles within
each vaccination group were assessed by comparing frequencies at
each analysis time-point withmean baseline values. Negative values
in antigen-speciﬁc ICS data generated by background subtraction
were replaced by a minimum threshold value [36].
Differences in the pathology scores, pulmonary disease mea-
sures and clinical measures of disease burden at the end of study
were compared between test groups using the non-parametric
Mann-Whitney U test, Minitab version 15 (Minitab Ltd, Coventry,
UK). Differences in the survival rates of animals in each test group
were compared with a log rank test using Minitab version 15 and
Gehan-Breslow-Wilcoxon test in Graphpad Prism, version 5.01
(GraphPad Software Inc, La Jolla, California, USA).
The Spearman correlation test was used to determine the level
of correlation between study parameters using GraphPad Prism,
version 5.01 (GraphPad Software Inc, La Jolla, California, USA).
3. Results
3.1. Safety of BCG delivery by alternative routes
All animals in the study showed the weight gain proﬁlesexpected in normal healthy animals during the period prior to
challenge. Temperature, erythrocyte sedimentation rate (ESR) and
red cell haemoglobin levels all remained within the normal range
during the post-vaccination and pre-challenge phase of the study.
Mild induration and erythema occurred at the site of BCG immu-
nisation in animals that received an intradermal vaccination with
BCG. Reactions appeared four weeks after BCG vaccination and
were completely resolved in animals by 16 weeks after immuni-
sation. Both intravenous and intra-tracheal delivery of BCG were
well tolerated and neither led to perturbations beyond normal
ranges in the clinical parameters measured.3.2. M. tuberculosis exposure and disease progression post-
challenge
The macaques were challenged with a median estimated
retained dose of 94 cfu (range 74e174) (Table 1) and the doses
were consistent across all the study groups. In the period after
aerosol challenge with M. tb, a proportion of animals in all four
study groups showed changes in behaviour and clinical parame-
ters consistent with progression of tuberculosis-induced disease
and were euthanized ahead of the planned end of the study.
These animals included ﬁve of the six naïve control group D (S23,
S33, S36, S40, S51), three of six ID BCG-vaccinated animals in
group A (S43, S6, S17), two of six ID þ IT BCG vaccinated animals
in group B (S42, S12) and one of six IV BCG vaccinated animals in
group C (S35), and all exhibited progressive weight loss, elevated
ESR levels, erythrocyte haemoglobin concentrations below the
normal range, tachypnoea and or dyspnoea and cough (red
symbols, Fig. 2EeH). None of the surviving animals in any
vaccination group showed adverse behavioural or pre-mortem
clinical indicators at the time of termination 17e20 weeks after
challenge (Fig. 2EeH).
The length of time that the animals in each group controlled
disease before levels progressed to reach clinical end-points (Fig. 3)
was compared using two statistical approaches: the Log Rank Test
and the Gehan-Breslow-Wilcoxon Test. Comparison of survival
times between each of the vaccination groups A, B and C and the
unvaccinated control group D revealed BCG vaccination improved
the control of TB-induced disease in the ﬁrst 17 weeks following
aerosol challenge. The difference in survival time reached statistical
signiﬁcance using the Log rank test only when BCG was given
intravenously (P ¼ 0.017), although the Gehan-Breslow-Wilcoxon
test suggested the differences to be signiﬁcant for all three BCG
vaccination regimens (IV: p ¼ 0.02; ID: p ¼ 0.05; ID þ IT: p ¼ 0.05).
Differences in survival time between vaccination groups were not
revealed by either test, between the group vaccinated with ID BCG
alone and the IV BCG vaccinated group.3.3. Measures of tuberculosis-induced disease burden
At the end of the study, the level of tuberculosis-induced disease
burdenwas determined using a range of approaches that have been
used previously for the evaluation of TB vaccine efﬁcacy in a rhesus
macaque aerosol challenge model [31] (Fig. 2). TB-induced disease
burden was higher in animals that met humane endpoint criteria
during the study than in those that controlled disease progression
to the end of the study. The gross pathology score determined at
necropsy, based on the number and size of lesions, revealed the
level of disease in all BCG vaccinated groups to be signiﬁcantly
lower than in the unvaccinated group in all groups (BCG IV:
p ¼ 0.01, BCG ID: p ¼ 0.05 and BCG ID/IT: p ¼ 0.05). Intravenous
vaccination with BCG also afforded a signiﬁcant improvement over
ID BCG vaccination (p ¼ 0.04) (Fig. 2D).
Table 1
Aerosol challenge doses of M. tuberculosis delivered to rhesus macaques.
Group Vaccine and route Animal Identiﬁcation number Presented Dose (cfu) Estimated Retained Dose (cfu)
Group A BCG ID S6 571 82
S14 535 76
S17 666 95
S22 632 90
S26 1215 174
S43 627 90
Group B BCG ID þ IT S12 647 92
S24 714 102
S42 773 111
S45 525 75
S58 535 76
S63 802 115
Group C BCG IV S4 688 98
S7 812 116
S19 744 106
S20 447 64
S35 1016 145
S61 802 115
Group D No vaccine S23 515 74
S33 525 79
S36 1176 168
S40 972 139
S51 622 89
S50 539 77
Study median 657 94
Route of delivery: ID: intradermal; IV: intravenous; IT: intratracheal.
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The pathology and imaging measures used to assess pulmonary
disease burden showed similar trends in outcome (Table 2). The
number of pulmonary lesions determined by serial sectioning and
manual counting of both discrete and coalesced lesions (Fig. 2B),
and the lung pathology scores (Fig. 2C), were signiﬁcantly less in
the BCG IV and BCG ID/IT groups than in the unvaccinated group.
Lung lesion counts also revealed IV vaccinationwith BCG afforded a
signiﬁcant improvement over ID vaccination with BCG. Thoracic
radiographic scores (Fig. 2E), pulmonary disease burden quantiﬁed
using stereology on MR images to determine the ratio between
total lesion volume and lung volume (Fig. 2 A), and terminal
measures of clinical parameters (Fig. 2F, G, H) revealed similar
generally non-signiﬁcant trends for the highest disease burden to
occur in the unvaccinated group, lower levels of disease in the BCG
ID and BCG ID/IT vaccinated groups, and the lowest level of disease
in the BCG IV group. There was a trend for the erythrocyte sedi-
mentation rate (ESR) to be lower in the BCG IV vaccinated group
than in the unvaccinated group, and red blood cell haemoglobin
concentrations were greater in the BCG ID/IT group than in the
unvaccinated group.
Microscopic, lung consolidation scores were highest in the un-
vaccinated group (score ¼ 148) compared to the vaccinated groups
(ID score ¼ 104; ID/IT score ¼ 99; IV score ¼ 80); furthermore,
discrete granulomas in this group lacked a ﬁbrous capsule. Lesions
in animals that received an intradermal vaccination with BCG were
less severe than those in the unvaccinated animals, but less well
organised than those in the BCG IV or BCG ID/IT vaccinated animals,
where granulomas had a caseated, occasionally calciﬁed centre, and
evidence of peripheral ﬁbrosis.
3.5. Extra-pulmonary disease burden
Evidence of dissemination to the hilar lymph nodes, liver, kid-
neys and spleen was evaluated by microscopic examination and by
culture of tissue samples for the presence of viable M. tb (Table 3).
Microscopic lesions were found more frequently in non-pulmonarytissues from unvaccinated animals and BCG ID vaccinated animals
than in tissues from BCG ID/IT and BCG IV vaccinated animals
(Table 3). Similarly,M. tbwas isolated from a reduced number of the
tissues collected from the BCG IV, or ID/IT vaccinated animals
compared to the tissues from the BCG ID, or unvaccinated groups
(Table 3). Where bacteria were isolated, the bacterial burden in
tissues was at a similar level in all study groups.
Taken together the results of microscopic examination and
bacterial culture show a lower level of disseminated disease in the
BCG IV vaccinated group as evidence of TB was only detected in a
single animal (S35) in the spleen, liver and kidneys, in the liver and
kidneys of a second animal (S20), and the kidneys of a third animal
(S4). In contrast, evidence of TB was found in the spleen, liver and
kidneys of all the unvaccinated animals, and the majority of the
BCG ID vaccinated animals (liver, six of six, spleen and kidneys ﬁve
of six). Dissemination frequency to the liver in the BCG ID/IT group
was equivalent to the BCG ID and unvaccinated groups; however,
there was a trend for reduced spread to the spleen (two of six) and
kidneys (three of six).
3.6. Immune response correlates
3.6.1. IFN-g response to vaccination/aerosol challenge with
M. tuberculosis
The mycobacterium-speciﬁc IFN-g response induced by vacci-
nation and challenge was measured using an ex-vivo ELISpot assay
applied at two weekly intervals through the study (Fig. 4) and
revealed differences in the response proﬁles of PPD-speciﬁc IFNg
secreting cells in BCG vaccinated and unvaccinated animals. The
response to BCG vaccination reached a peak six weeks after intra-
venous (group C Fig. 4C), or intradermal administration (group A,
Fig. 4 A). The response proﬁle in BCG ID/IT immunised animals
(group B) showed a second peak at week 12, one week after intra-
tracheal delivery of the second dose of BCG (Fig. 4B). During the
same period, responses remained uniformly low in the unvacci-
nated animals (group D, Fig. 4D). The frequency of PPD-speciﬁc IFN-
g secreting cells was signiﬁcantly higher in BCG vaccinated groups
(Group A, ID versus Group D: p ¼ 0.005; Group ID/IT versus Group
Fig. 2. Measures of tuberculosis-induced pulmonary and clinical disease burden. Panel A: the lung to lesion volume ratio determined using MR stereology; Panel B: number of
lesions in the lung enumerated by serial sectioning and manual counting; Panel C: the score attributed to the pulmonary component as part of the total pathology; Panel D: the total
pathology score determined using a qualitative scoring system; Panel E: score attributed to the chest radiogram on the day of euthanasia; Panel F: % weight loss from peak post-
challenge weight on the day of euthanasia; Panel G: Erythrocyte sedimentation rate (ESR) on the day of euthanasia; Panel H: bacterial load in the lung. Red shading indicates
animals in which disease reached endpoint criteria. P values are shown and * denotes signiﬁcant difference in outcome between groups using the non-parametric Mann-Whitney U
test, p  0.05.
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Fig. 3. Kaplan Meier plot of survival of vaccinated and unvaccinated NHPs after
challenge with M. tuberculosis.
Table 2
Statistical analysis of the differences between test groups using different vaccine
efﬁcacy readouts.
Measure P Value*
Test group compared to No
vaccine
Test group
compared to BCG ID
BCG ID BCG ID/IT BCG IV BCG ID/IT BCG IV
Lesion: Lung volume 0.81 0.26 0.13 0.81 0.13
Lung lesion 0.46 0.04 0.04 0.10 0.04
Count
Pathology 0.05 0.05 0.01 0.58 0.04
Score
Lung score 0.08 0.01 0.01 0.58 0.07
Thoracic radiograph 0.17 0.20 0.08 0.87 0.63
% weight loss 0.41 0.29 0.06 0.86 0.45
RBC [Hb] 0.38 0.03 0.09 0.81 0.17
ESR 0.23 0.38 0.05 0.20 0.30
 Mann Whitney test. Route of delivery: ID: intradermal; IV: intravenous; IT:
intratracheal.
Bold text indicates values less than or equal to 0.05. P  0.05.
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vaccinated animals in the period between vaccination and chal-
lenge. The group that received BCG by the intravenous route made
the largest PPD-speciﬁc response during the 20 week period after
vaccination, and statistical analysis using AUC and Mann Whitney
tests conﬁrmed the response to be signiﬁcantly greater than the
responses induced by BCG following either a single intradermal
vaccination (p ¼ 0.005) or an intradermal prime - intratracheal
boost regimen (p ¼ 0.0202). The PPD-speciﬁc IFN-g secreting cell
proﬁle induced by the BCG ID prime/IT boost regimen, although
increased, was not signiﬁcantly different to the proﬁle induced by a
single intradermal BCG vaccination (p ¼ 0.093) over the 20 week
period. However, between weeks 12 and 20, the second BCG
vaccination in the regimen boosted the response to a level com-
parable to that detected following BCG IV vaccination (p ¼ 0.689),
and greater than that in the BCG ID vaccination group (p ¼ 0.031).
Responses measured 20 weeks after vaccination just prior to
challenge were signiﬁcantly greater in both the BCG IV group
(p ¼ 0.005) and the BCG ID prime/IT boost group (p ¼ 0.03) than in
the unvaccinated control group, in contrast to response in the BCG
ID group (p ¼ 0.11).
After aerosol challenge with M. tb, the PPD-speciﬁc IFN-g re-
sponses induced in the BCG vaccinated groups (A, B, C) were lower
than those induced in the unvaccinated group (D) and lowest in
group C which received BCG by intravenous injection. Statistical
comparison of responses between test groups was only valid in theearly phase after infection while all animals remained in the study.
Analysis of the responses during the ﬁrst four weeks after infection
veriﬁed the PPD-speciﬁc IFN-g response to be signiﬁcantly lower in
BCG vaccinated groups (Group A, ID versus Group D no vaccine:
p ¼ 0.031; Group B ID/IT versus Group D, no vaccine: p ¼ 0.005;
Group C IV versus Group D, no vaccine: p ¼ 0.005) than in the
unvaccinated animals. The responses measured in the groups that
received BCG, either intravenously (group C) or in an ID/IT prime
boost regimen (group B), were equivalent (p ¼ 0.34) and both were
signiﬁcantly lower than the response measured in the group that
received BCG by intradermal injection (p ¼ 0.005).
The Spearman's Rank correlation test was applied to evaluate
potential relationships between the frequency of PPD-speciﬁc IFN g
secreting cells induced by vaccination, or challenge and the TB-
induced disease burden evaluated at termination using a range of
measures, including gross pathology score, pulmonary lesion
counts, lesion to lung volume ratio and changes in clinical param-
eters. Signiﬁcant relationships between measures were not iden-
tiﬁed within individual test groups.
When results from all animals in the study were combined and
tested, a higher frequency of IFNg secreting cells (AUC) during the
20 week period after vaccination showed a statistically signiﬁcant
correlation with lower disease burden after challenge (total pa-
thology score p ¼ 0.004, lung score, p ¼ 0.002, pulmonary lesion
count, p ¼ 0.005, % weight loss, p ¼ 0.012, terminal ESR p ¼ 0.04,
terminal red blood cell haemoglobin concentration, p ¼ 0.03).
Similarly, a high frequency of IFNg secreting cells after challenge
signiﬁcantly correlated with decreased survival time and higher
levels of disease burden measured.
3.6.2. Polyfunctional CD4 and CD8 T-cell proﬁles
Frequencies of CD4 and CD8 T-cells producing combinations of
the cytokines IFN-g, IL-2 and TNF-a in response to antigenic stim-
ulation with tuberculin PPD were measured in PBMC samples
collected at selected time points throughout the study. Antigen
speciﬁc CD4 T-cells were found to primarily occupy three distinct
functional proﬁles, which were producing all three cytokines
simultaneously (polyfunctional T-cells), IFN-g and TNF-a in unison,
or TNF-a alone (Fig. 5a). Frequencies of multiple cytokine producing
CD4 T-cell populations increased signiﬁcantly relative to pre-
vaccination levels following both ID and IV vaccination in all
immunisation groups (P  0.04). Polyfunctional populations were
apparent from six weeks following IV BCG vaccination but
remained undetected in other vaccination groups until week 10
(Fig. 5a). There was a trend for higher frequencies of multifunc-
tional CD4 T-cells to be detected during the vaccination phase (up
to week 20) following IV vaccination, and this response persisted
throughout the post-vaccination period. Comparisons between the
groups revealed that these elevated frequencies only reached sta-
tistical signiﬁcance at study week 12, relative to the ID BCG vacci-
nation group (p ¼ 0.025). An increased frequency of IFN-g and TNF-
a dual cytokine secreting cells, suggestive of a boosting response,
was apparent in the ID þ IT vaccination group one week after
intratracheal BCG inoculation. However, this was not found to be
signiﬁcantly different from frequencies of the equivalent popula-
tion measured in either the ID or IV vaccinated animals (p ¼ 0.055
and 0.75, respectively), although the difference between ID and
ID þ IT vaccinated groups approached statistical signiﬁcance.
M.tb aerosol challenge induced an anamnestic CD4 T-cell
response in the ID and ID þ IT vaccinated animals, as shown by
increased frequencies of polyfunctional T-cells and those producing
IFN-g and TNF-a simultaneously four weeks following exposure.
However, frequencies remained low in IV vaccinated animals
relative to other vaccination groups and unvaccinated controls, and
were comparable to levels detected during the vaccination phase of
Table 3
Evidence of extra-pulmonary TB-induced disease from microscopic examination and bacterial culture.
Group Vaccine ID Evidence of TB
Hilar LN Spleen Liver Kidney
Individual Group (N/
6)
Individual Group (N/
6)
Individual Group(N/
6)
Individual Group(N/
6)
M BC M BC M BC M BC M BC M BC M BC M BC
A BCG
ID
S6 þ þ þ þ þ þ þ þ
S14 þ þ þ þ þ þ þ e
S17 þ þ 6 6 þ þ 4 5 þ þ 5 4 þ þ 5 3
S22 þ þ e e þ e þ e
S26 þ þ þ þ þ e þ e
S43 þ þ þ þ e þ e þ
B BCG
ID þ IT
S12 þ þ e þ þ þ þ þ
S24 þ e e e þ e e e
S42 þ þ 6 5 e e 0 2 þ þ 5 3 þ e 3 2
S45 þ þ e e þ e e e
S58 þ þ e e þ þ þ þ
S63 þ þ e þ e e e e
C BCG
IV
S4 þ e e e e e þ e
S7 e e e e e e e e
S19 e þ 4 3 e e 1 1 e e 2 1 e e 3 1
S20 þ e e e þ e þ e
S35 þ þ þ þ þ þ þ þ
S61 þ þ e e e e e e
D No Vaccine S23 þ þ e þ þ þ þ þ
S33 þ þ þ þ þ þ þ þ
S36 þ þ 6 5 þ þ 5 6 þ þ 6 6 þ þ 6 6
S40 þ þ þ þ þ þ þ þ
S51 þ þ þ þ þ þ þ þ
S50 þ e þ þ þ þ þ þ
ID: Identiﬁcation number; LN: lymph node; M: microscopic examination; BC: bacterial culture; ¡: feature not present; þ: feature present; N/6 where N is the number of
animals in which evidence of TB infection was determine in the tissue by either bacterial culture or microscopic examination. Route of delivery: ID: intradermal; IV:
intravenous; IT: intratracheal.
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detected in the IV and ID þ IT vaccination groups following M.tb
aerosol challenge, but not in animals receiving ID BCG or no
vaccination. M.tb speciﬁc immune responses in the unvaccinated
control group did not exceed baseline levels until four weeks after
M.tb aerosol challenge.
A Spearman's rank correlation analysis applied to determine the
dependence between cytokine producing CD4 T-cell frequency and
disease outcome indices measured at necropsy revealed a weak,
but signiﬁcant, negative correlation between the frequency of CD4
T-cells simultaneously producing IFN-g and TNF-a measured in
vaccinated animals at study week 6, and reduced lung and total
pathology score (p ¼ 0.005 and p ¼ 0.018, respectively) (Fig. 6a and
b). Furthermore, the inverse relationship was observed when this
analysis was repeated using CD4 T-cell frequencies measured four
weeks following M.tb challenge, with greater IFN-g and TNF-a
producing multifunctional CD4 T-cell frequencies correlating with
increased lung and total pathology (p ¼ 0.002 and 0.007) (Fig. 6 c
and d). Frequencies of polyfunctional CD4 T-cells did not correlate
with disease outcome measures, although a weak, non-signiﬁcant
(p ¼ 0.069), relationship was indicated six weeks following pri-
mary BCG vaccination Fig. 6e).
The functional proﬁle of CD8 T-cell populations was primarily
split between cells producing IFN-g and TNF-a simultaneously and
those producing only TNF-a (Fig. 5b). These populations were
detected in all BCG vaccination groups following immunisation,
although frequencies rarely reached signiﬁcance above pre-
vaccination levels. A signiﬁcant increase in the frequency of poly-
functional CD8 T-cells was detected four weeks following M.tb
challenge in the unvaccinated control animals (p ¼ 0.004), and was
accompanied by elevated frequencies of IFN-g and TNF-a producing
populations (p ¼ 0.004).3.6.3. Memory CD4 and CD8 T-cell proﬁles
To establish the memory differentiation status of antigen-
speciﬁc CD4 and CD8 T-cells, cytokine producing central and
effector memory populations were identiﬁed in each subset as cells
producing any of the cytokines IFN-g, IL-2 or TNF-a and the acti-
vation marker CD95, followed by expression patterns of the co-
stimulatory receptor CD28 and lymph node homing marker CCR7.
Therefore, central to effector T-cell differentiation was determined
on antigen-speciﬁc CD4 and CD8 T-cells as (TCM) CD28þCCR7þ;
CD28þCCR7- transitional effector memory (TransEM); and fully
differentiated (TEM) CD28CCR7 (Fig. 7b and d).
Antigen-speciﬁc CD4 T-cells measured following BCG vaccina-
tion and M.tb challenge were primarily of the TransEM phenotype,
expressing CD28 but not CCR7 (Fig. 7a). IV BCG vaccination induced
a sustained antigen-speciﬁc TransEM response, with frequencies of
this population signiﬁcantly higher than those measured in the ID
BCG vaccination group at weeks six, 12 and 20 post-vaccination
(p ¼ 0.037, 0.025 and 0.025, respectively). A strong boosting
response was evident in the ID þ IT vaccination group one week
following IT BCG delivery (study week 12), with frequencies of
cytokine producing TransEM populations signiﬁcantly above either
ID or IV BCG vaccinated groups at this time point (p ¼ 0.004 and
p ¼ 0.004, respectively). Anamnestic cytokine responses were
detected followingM.tb challenge in the TransEM populations of ID
and IDþ IT BCG vaccinated animals, whereas the median frequency
of cytokine producing TransEM CD4 T-cells measured in the IV
vaccination group two and four weeks (study week 23 and 25)
following M.tb inoculation, remained statistically equivalent to
frequencies measured one week prior (study week 20) to challenge
(p ¼ 0.749 and 0.873, respectively). Antigen-speciﬁc TransEM fre-
quencies were signiﬁcantly above that of the unvaccinated controls
at study week 23 in all vaccination groups (p ¼ 0.037 and p ¼ 0.025
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Fig. 4. Immune response to vaccination and challenge: The frequency of PPD-speciﬁc IFN-g secreting cells measured after BCG vaccination and challenge measured by ELISpot.
Panel A: response proﬁle in Group A which received BCG as a single intradermal injection; Panel B: response proﬁle in Group B which received BCG in a BCG ID prime/IT boost
regimen; Panel C: response proﬁle in Group C which received BCG as a single intravenous injection and Panel D shows the response in Group D which did not receive BCG
vaccination. Vaccination with BCG at week 0 is indicated by the dashed line, intra-tracheal vaccination with BCG indicated by the dotted line at week 12 and aerosol exposure to
M. tuberculosis indicated by the long dashed line at week 21.
S. Sharpe et al. / Tuberculosis 101 (2016) 174e190 183for ID and ID þ IT or IV, respectively). However, by study week 25
(four weeks post M.tb challenge), antigen-speciﬁc CD4 TransEM
populations were statistically equivalent when compared across
the treatment groups (p > 0.05), although there was a non-
signiﬁcant trend for frequencies of cytokine producing TransEM
cells in the unvaccinated controls to exceed that of the BCGvaccinated animals. At this time-point, frequencies of antigen-
speciﬁc TransEM cells measured in the IV vaccinated animals
appeared lower than those of the other treatment groups,
approaching signiﬁcance in relation to the unvaccinated controls
and ID vaccinated animals (p ¼ 0.055 and 0.078, respectively).
Antigen-speciﬁc CD4 TCM populations were detected in all BCG
Fig. 5. PPD-speciﬁc polyfunctional CD4 and CD8 T-cell responses. Bar charts represent vaccination group median values of cytokine producing CD4 T-cells (plot A) and CD8 T cells
(plot B) isolated prior to vaccination (PB) and at study weeks 6, 10, 12, 20, 23 and 25. Note that all vaccinated animals received BCG vaccinations at week 0 by intravenous (IV), or
intradermal (ID and ID þ IT) injection, and that the ID þ IT vaccination group received a further intratracheal BCG inoculation at study week 11. Polyfunctional T-cell responses
measured in unvaccinated controls are shown at PB and weeks 23 and 25. All animals received aerosol M.tb challenge at study week 21. Shaded areas depict immune responses
measured following M.tb challenge. Cytokine frequencies in individual animals are represented by dots. Horizontal bars denote signiﬁcant changes from mean pre-vaccination
values as measured by Wilcoxon signed rank test (p  0.05).
Fig. 6. Correlation plots comparing the frequency of PPD-speciﬁc CD4 T-cell populations with disease outcome measured by either lung (A, C and E) or total (B and D) pathology
scores. Plots A and B show correlations between outcome and the frequency of PPD-speciﬁc CD4 T-cells producing IFN-g and TNF-a simultaneously at six weeks following primary
BCG vaccination; Plots C and D show correlations between outcome and the frequency of PPD-speciﬁc CD4 T-cells producing IFN-g and TNF-a simultaneously four weeks following
aerosolM. tuberculosis infection; Plot E shows a correlation plot comparing the frequency of PPD-speciﬁc polyfunctional CD4 T-cells producing IFN-g, IL-2 and TNF-a simultaneously
six weeks following primary BCG vaccination with disease outcome as measured by lung pathology score. Data points represent individual animals, and vaccination groups are
indicated by colour. Spearman's correlation coefﬁcient (r) and signiﬁcance values (p) are indicated.
S. Sharpe et al. / Tuberculosis 101 (2016) 174e190 185vaccination groups six and ten weeks after vaccination, and in ID
vaccinated animals 12 weeks following vaccination, but were ab-
sent, or only detectable at low frequencies at later vaccination
phase time points and following M.tb challenge (Fig. 7a). Fre-
quencies of antigen-speciﬁc CD4 TEM populations were detected at
low levels throughout the study and remained comparable be-
tween the treatment groups (Fig. 7a).
Cytokine production in antigen-speciﬁc CD8 memory T-cell
populations was more evenly split between TransEM and TEM
populations and remained relatively consistent during the period
between BCG vaccination and M.tb challenge (Fig. 7c). No signiﬁ-
cant differences were detected between the BCG vaccinationgroups in terms of cytokine producing CD8 memory T-cell pop-
ulations. However, the frequency of antigen-speciﬁc TransEM cells
measured in the unvaccinated controls was signiﬁcantly greater
than that observed in the IV BCG vaccine group (p ¼ 0.016), and
approached signiﬁcance relative to ID þ IT and ID BCG vaccinated
animals (p ¼ 0.055 and 0.078, respectively), at study week 25.3.6.4. Correlations between immunological assays
The ex vivo IFN-g ELISpot assay applied throughout this study is
commonly assumed to provide a rapid readout of Th1 effector T-cell
function. To investigate the relationship between PPD-speciﬁc im-
mune responses measured by IFN-g ELISpot and antigen-speciﬁc
Fig. 7. Antigen-speciﬁc CD4 and CD8 memory T-cell proﬁles measured in PBMCs. Plots A and C, show representative bivariate density plots showing central to effector memory T-
cell populations, deﬁned by patterns of CD28 and CCR7 staining on CD95 expressing CD4 (A) and CD8 (C) T-cells, overlaid with cytokine producing cells represented as dots. Plot B
displays the frequency of antigen-speciﬁc cytokine producing memory CD4 T-cell populations during the vaccination and M.tb infection phase of the study. Box plots show
interquartile range with medians indicated. Plot C displays the frequency of antigen-speciﬁc cytokine producing memory CD8 T-cell populations during the vaccination and M.tb
infection phase of the study. Box plots show interquartile range with medians indicated.
S. Sharpe et al. / Tuberculosis 101 (2016) 174e190186memory T-cell phenotype, Spearman's correlation analysis was
used to compare IFN-g SFU and antigen-speciﬁc CD4memory T-cell
frequencies measured at equivalent time-points (Fig. 8). This
revealed signiﬁcant correlations between IFN-g SFU measured by
ELISpot assay and antigen-speciﬁc CD4 transitional effector mem-
ory T-cell frequency at study weeks six, 12, 23 and 25 post-
vaccination (p ¼ 0.0001 to 0.02, r ¼ 0.515 to 0.867, respectively).
This indicated that ex vivo IFN-g SFU measured by ELISpot assay
provides a useful measure of CD4 TransEM activity.4. Discussion
The contribution of non-human primate models in the devel-
opment of new TB vaccines would be revolutionised by the iden-
tiﬁcation of a vaccine strategy that can confer a clear protective
effect against M. tb challenge. The efﬁcacy afforded by such a
strategy would enable identiﬁcation of immune correlates of pro-
tection that could inform the development of new vaccines and
would also provide a bench mark against which their efﬁcacy could
Fig. 8. Relationship between PPD-speciﬁc IFN-g SFUmeasured by ELISpot and frequency of antigen-speciﬁc CD4 TransEM populations. Correlation plots comparing the PPD-speciﬁc
SFU measured by ELISpot and frequency of antigen-speciﬁc CD4 Transitional effector T-cell populations at six (A), 12 (B), 23 (C) and 25 (D) weeks following primary BCG vaccination.
Note that week 23 and 25 also correspond to weeks two and four following aerosol M. tuberculosis infection, respectively (C and D). Data points represent individual animals.
Spearman's correlation coefﬁcient (r) and signiﬁcance values (p) are indicated. A linear regression line is included for reference.
S. Sharpe et al. / Tuberculosis 101 (2016) 174e190 187be tested. This study has revealed that BCG when delivered intra-
venously has the potential to fulﬁl this role.
As the primary aim of this study was to identify vaccine stra-
tegies with enhanced protective efﬁcacy against aerosol exposure
to M. tb, the BCG doses used for administration were selected to
increase the protective effect afforded by BCG for the speciﬁc route
and not matched across delivery routes, although a limitation of
this strategy precluded the dissection of the contribution of dose
and route to the protective effects identiﬁed. As in previous vaccine
evaluation studies in the rhesus macaque model (Sharpe 2010,
Verreck 2009), and in line with the guidelines for the use of TB
models of tuberculosis (Flynn, Reed & Langermans 2004), the dose
recommended for intradermal immunisation of humans from an
age of two years was selected for intradermal delivery to the ma-
caques in groups A and B. The BCG dose selected for intravenous
(group C) and intra-tracheal delivery (group B) were derived using
a pragmatic approach. Following a review of early studies [9e12], in
which large doses of older BCG strains were used, it was not
possible to equate the doses quoted to exact levels of the current
BCG SSI vaccine, beyond the implication that the doses used were
larger than the standard human ID dose. Therefore, to mitigate risk
of inducing adverse events, a dose 10 fold higher than the ID doses
was selected as this has previously been shown to be well tolerated
following delivery directly to the lungs (Sharpe et al., unpublished
observations).4.1. BCG dose and route inﬂuence TB-induced disease burden and
dissemination
The single intradermal BCG vaccination (group A) conferred a
signiﬁcant improvement in the ability to control disease progres-
sion in the 17 week period after aerosol exposure and the overall
disease burden measured as total gross pathology score in com-
parison to the outcome in unvaccinated animals. The level of efﬁ-
cacy measured for BCG delivered intradermally in the rhesus
macaques in this study is consistent a previous study [31], which
suggests that BCG can induce a consistent level of protectionwithin
this model. In addition to the improvements in disease control and
overall disease burden induced by intradermal delivery of BCG
alone, the application of a second vaccination, with BCG delivered
directly to the lung to form a BCG ID prime/BCG IT boost regimen,
led to a reduction in the level of pulmonary disease. The improved
outcome afforded by BCG revaccination in this study is consistent
with that seen in clinical trials [15,16] and studies in other animal
models [13,14]. Although further work is required to determine the
role of the delivery route and dose in the effect afforded, there have
been no previous reports of BCG boosting vaccinations delivered
directly to the macaque lung in a heterologous revaccination
regimen, so the strong systemic immunogenicity observed in this
study, and the improved outcome is a noteworthy proof of concept.
Whilst intratracheal administration may not be a practical
approach for mass vaccination campaigns, other mucosal
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tract may prove a more viable strategy. Indeed an improved pro-
tective effect has been reported following delivery of BCG by
aerosol, either as a primary vaccination in macaques [10] or as a
booster in mice [37],
BCG delivered intravenously led to signiﬁcantly improved out-
comes compared to those in the unvaccinated group and the BCG ID
vaccinated group, which is consistent with studies from the 1970's
[9e12]; however, the study reported here provides further evi-
dence of the robustness of the protective effect induced by IV
vaccination, as a higher dose of the more virulent strain
M. tuberculosis Erdman [38] was used for aerosol challenge.
Although the intravenous route is not currently considered for use
in clinical studies, this does not preclude the use of this delivery
route in non-human primate studies to provide the standard
against which new vaccines can be compared, or as a tool for the
investigation of potential correlates of protection.
4.2. Polyfunctional T cell induction by Mycobacteria
Multifunctional T-cells are known to be a component of the
response to M. tb infection in humans [23,39e42], and in non-
human primates [31,43], and there is evidence to suggest that
vaccine-induced multifunctional T-cell populations may correlate
with improved outcome following virulentM. tb challenge [43,44].
This study conﬁrms that polyfunctional T-cells expressing IFN-g, IL-
2 and TNF-a are induced by parenteral BCG vaccination strategies
including ID and IV application. Furthermore, elevated frequencies
of polyfunctional CD4 populations were also detected following
high doseM. tb challenge, particularly in unvaccinated animals and
the ID or ID þ IT study groups which developed relative high levels
of disease pathology in comparison to the IV vaccination group.
This conﬁrms that these T-cell populations are involved in the
response during the active phase of disease [23,39e42] and in-
dicates a possible link between polyfunctional T-cell frequency and
pathogen-derived antigenic load [45]. In addition to polyfunctional
cells producing IFN-g, IL-2 and TNF-a, it was found that a major
component of the BCG-inducedmultifunctional T-cell responsewas
accounted for by CD4 T-cells producing IFN-g and TNF-a in unison.
Frequencies of this dual functional CD4 T-cell population remained
elevated throughout the vaccination phase of the study, regardless
of BCG vaccination route or regimen, and early post vaccination
frequencies correlated signiﬁcantly with reduced total and lung
pathology score following subsequent aerosol M. tb challenge
(Fig. 7). However, high frequencies of IFN-g and TNF-a producing
CD4 T-cells were also detected following M. tb challenge in un-
vaccinated controls and in the animals receiving less protective
vaccination regimens (ID and ID þ IT). Correlation analysis applied
at this stage of the study revealed a signiﬁcant relationship be-
tween the frequency of this T-cell population and the development
of pulmonary and disseminated disease pathology (Fig. 7). These
correlative analyses indicate that CD4 T-cells producing IFN-g and
TNF-a simultaneously are a key effector population in the
mycobacteria-speciﬁc T-cell response, including during the early
stages of M. tb infection, and is in agreement with observations
reported from functional T-cell studies conducted using samples
from active TB patients [46].
In contrast to the functional repertoire observed in CD4 T-cells,
signiﬁcant increases in the frequency of multifunctional CD8 sub-
sets were only detected in unvaccinated control animals, four
weeks following M. tb exposure. However, as low levels of IFN-g
and TNF-a secreting CD8 population were detected in the IV BCG
vaccinated animals, which persisted until time-points immediately
prior to M. tb challenge, these cells may have contributed to the
strong protective efﬁcacy observed in this group.4.3. Protection associated with mycobacterial antigen-speciﬁc CD4
effector memory T-cell populations
Intradermal BCG vaccination is known to protect infants and
children against severe disseminated forms of TB [47,48]. However,
this protective immunity is less evident in the adult population for
whom the efﬁcacy of BCG vaccination is highly variable [4,49].
Conventionally, the phenotypic composition of the vaccine-
induced memory T-cell population is considered indicative of the
long-term persistence of the vaccine mediated response, with TCM
populations key to long term immunity [50,51]. It has been sug-
gested that a poor capacity to induce TCM populations is an un-
derlying factor in the failure of BCG to protect beyond adolescence
in the human population [29], and the BCG mediated memory T-
cell response has been shown to favour induction of effector T-cell
populations [28,52]. The antigen-speciﬁc memory T-cell analysis
applied during this study provides further evidence thatmemory T-
cell populations induced by BCG vaccination are biased toward an
effector phenotype, with the CD4 transitional effector memory T-
cell population found to dominate the antigen-speciﬁc vaccine
induced response, as well as the response to M. tb infection. This
ﬁnding is in close agreement with memory T-cell frequencies
observed in human TB infection where an analogous effector T-cell
population, expressing the same proﬁle of cytokines, has been
shown to predominate in peripheral blood samples collected from
active TB patients [46]. In our study, IV BCG inoculation induced a
sustained expansion of this systemic mycobacterial antigen-
speciﬁc CD4 effector memory population, which remained signiﬁ-
cantly elevated above that observed in ID BCG vaccinated animals
one week prior to M. tb challenge (P ¼ 0.025). Heightened
mycobacteria-speciﬁc CD4 TEM responses prior to infection may
represent a potential biomarker of protection against high dose
M. tb challenge.
IFN-g ELISpot proﬁles and the antigen-speciﬁc memory T-cell
response identiﬁed the lack of a systemic, anamnestic response
post-M. tb challenge in the highly protected IV BCG vaccination
group. It is possible that immunological control was enacted at the
primary site of infection through heightened levels of CD4 effector
T-cell activity within the lung and associated lymphoid tissues,
although increased activation and activity from the innate com-
ponents of the cellular immune response may also have contrib-
uted to this control. This observation is analogous to the recent
ﬁndings reported from rhesus macaque studies investigating the
efﬁcacy of cytomegalovirus (CMV) vectored vaccine constructs
against experimental simian immunodeﬁciency virus (SIV) infec-
tion [53]. These vaccine constructs were designed to persist within
the host organism as a strategy to maintain elevated frequencies of
SIV-speciﬁc effector T-cell populations, and have been shown
capable of imparting signiﬁcant and long term protection against
high dose mucosal SIV challenge. Interestingly, whilst increased
post-vaccination frequencies of SIV-speciﬁc effector memory T-cell
populations were shown to correspond to the likely subsequent
control of SIV infection, animals which controlled disease made no
post-SIV challenge anamnestic response, thus indicating that vac-
cine induced effector T-cell populations were able to control the
infectious challenge within the mucosal tissues during the early
stages of infection [53,54]. As innate mechanisms were unlikely to
be responsible for protection against SIV infection [55,56], these
studies strongly support the premise that effector T-cell pop-
ulations were responsible for the protection imparted by these
vaccination regimens, although the mechanism remains to be
elucidated [53,54]. Nevertheless, as the BCG-induced T-cell
response clearly supported the induction of CD4 effector memory
T-cell responses, there is a clear parallel between the immunolog-
ical parameters and protection observed in our study and those
S. Sharpe et al. / Tuberculosis 101 (2016) 174e190 189observed following vaccination with the protective CMV/SIV
effector T-cell targeted vaccination strategy. Further studies con-
ducted over extended timescales are required to assess the likely
persistence of this protection, and to establish whether high fre-
quencies of IV BCG-induced mycobacteria-speciﬁc effector T-cell
populations are able to impart long term protection against M. tb
infection and disease.
5. Conclusion
This study has shown that BCG vaccination was able to signiﬁ-
cantly reduce disease severity induced by high dose aerosol M. tb
challenge in the rhesus macaque model, and that this protection
can be improved by mucosal BCG revaccination regimens or by
systemic BCG vaccination delivered intravenously. Whilst it is rec-
ognised that neither IV nor IT BCG delivery strategies are appro-
priate for deployment in the clinical setting, recent NHP vaccine
evaluation studies and early stage clinical trials have demonstrated
that alternative vaccination strategies such as aerosol delivery are a
practical, safe and immunogenic approach for the delivery of TB
vaccines [43,44,57e60]. The identiﬁcation of IV-delivered BCG as a
highly protective vaccination strategy may prove a pivotal step
towards deciphering protective immunological mechanisms
againstM. tb infection in pre-clinical models, potentially leading to
the identiﬁcation of immune correlates of protection, which could
be used to accelerate the vaccine development pipeline.
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